ImmunoCellular Therapeutics (IMUC) Price & Analysis

187 Followers

IMUC Stock Chart & Stats

$0.21

$0.03(13.96%)

At close: Jul 27 4:00 PM EDT

$0.21

$0.03(13.96%)

Day’s Range― - ―

52-Week Range$0.04 - $0.34

Previous CloseN/A

Volume3.69K

Average Volume (3M)9.99K

Market Cap

$26.41M

Enterprise Value$32.30M

Total Cash (Recent Filing)$613.24K

Total Debt (Recent Filing)$3.47M

Price to Earnings (P/E)―

Beta-0.23

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding126,502,860

10 Day Avg. Volume23,818

30 Day Avg. Volume9,991

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)-3.75

Price to Sales (P/S)0.00

P/FCF Ratio-6.01

Enterprise Value/Market Cap1.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-102.41

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IMUC FAQ

What was ImmunoCellular Therapeutics’s price range in the past 12 months?

ImmunoCellular Therapeutics lowest stock price was $0.04 and its highest was $0.34 in the past 12 months.

What is ImmunoCellular Therapeutics’s market cap?

ImmunoCellular Therapeutics’s market cap is $26.41M.

When is ImmunoCellular Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were ImmunoCellular Therapeutics’s earnings last quarter?

ImmunoCellular Therapeutics released its earnings results on Aug 13, 2018. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.1.

Is ImmunoCellular Therapeutics overvalued?

According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ImmunoCellular Therapeutics pay dividends?

ImmunoCellular Therapeutics does not currently pay dividends.

What is ImmunoCellular Therapeutics’s EPS estimate?

ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ImmunoCellular Therapeutics have?

ImmunoCellular Therapeutics has 126,502,860 shares outstanding.

What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?

ImmunoCellular Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?

Currently, no hedge funds are holding shares in IMUC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ImmunoCellular Therapeutics

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medications. These treatments hold the potential to revolutionize existing therapeutic approaches. Among its key drug candidates currently undergoing development are EOM613 and EOM147. Established on March 20, 1987, the company maintains its corporate headquarters in Montvale, New Jersey.